Odile Richard-Le Goff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Odile Richard-Le Goff has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J. Murphy
Regeneron Pharmaceuticals, Tarrytown, USA
1 shared publication - Bianca Balbino
Argenx, Zwijnaarde, Ghent, Belgium
1 shared publication - Bruno Iannascoli
Institut Pasteur, Université Paris Cité, Inserm UMR1222, Antibodies in Therapy and Pathology, 75015 Paris, France
1 shared publication - Delphine Sterlin
Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France
1 shared publication - Faith M. Harris
Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA
1 shared publication - Gael A. Millot
Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub
1 shared publication
Latest Publications
- 2 March 2020
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (3) , 1330-1335
The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors
Omalizumab is an anti-IgE monoclonal antibody (mAb) approved for the treatment of severe asthma and chronic spontaneous urticaria. Use of omalizumab is associated with reported side effects ranging from local skin inflammation at the injection site to systemic anaphylaxis. To date, the mechanisms through which omalizumab induces adverse reactions are still unknown. Here, we demonstrated that immune complexes formed between omalizumab and IgE can induce both skin inflammation and anaphylaxis through engagement of IgG receptors (FcγRs) in FcγR-humanized mice. We further developed an Fc-engineered mutant version of omalizumab, and demonstrated that this mAb is equally potent as omalizumab at blocking IgE-mediated allergic reactions, but does not induce FcγR-dependent adverse reactions. Overall, our data indicate that omalizumab can induce skin inflammation and anaphylaxis by engaging FcγRs, and demonstrate that Fc-engineered versions of the mAb could be used to reduce such adverse reactions.
- 2 March 2020
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (3) , 1330-1335
The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors
Omalizumab is an anti-IgE monoclonal antibody (mAb) approved for the treatment of severe asthma and chronic spontaneous urticaria. Use of omalizumab is associated with reported side effects ranging from local skin inflammation at the injection site to systemic anaphylaxis. To date, the mechanisms through which omalizumab induces adverse reactions are still unknown. Here, we demonstrated that immune complexes formed between omalizumab and IgE can induce both skin inflammation and anaphylaxis through engagement of IgG receptors (FcγRs) in FcγR-humanized mice. We further developed an Fc-engineered mutant version of omalizumab, and demonstrated that this mAb is equally potent as omalizumab at blocking IgE-mediated allergic reactions, but does not induce FcγR-dependent adverse reactions. Overall, our data indicate that omalizumab can induce skin inflammation and anaphylaxis by engaging FcγRs, and demonstrate that Fc-engineered versions of the mAb could be used to reduce such adverse reactions.